Taken together, these data strongly suggest that the CDK7 inhibitor can block RNAPII loading at the BETi resistance-specific PVT1 enhancer to suppress MYC transcription, thereby exerting a synergistic anticancer effect toward BETi-resistant leukemia. The gene discussed is PVT1; the disease is leukemia.